Business Context and Reporting Period
Company: Phase III Medical, Inc. (Note: Metadata listed "Lisata Therapeutics," but the filing text identifies the registrant as Phase III Medical, Inc.)
Reporting Period: Quarter and nine months ended September 30, 2005.
Business Model: The Company provides capital and consulting to healthcare and life sciences companies in exchange for revenue/royalty interests. Current operations consist of the "run-off" of a legacy internet warranty business and new ventures in the medical/bio-tech sector. The Company has not yet received payments from its new royalty interests.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2005 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Revenue | $28,201 | $37,383 |
| Gross Profit | $8,431 | $11,275 |
| Operating Loss | $(1,110,440) | $(1,211,738) |
| Net Loss | $(1,218,087) | $(1,448,881) |
| Cash Used in Operations | $(477,491) | $(1,120,064) |
| Cash Provided by Financing | $460,000 | $1,374,487 |
| Cash Balance (End of Period) | $10,377 | $461,436 |
| Total Current Liabilities | $1,872,276 | $1,288,050 |
| Stockholders' Deficit | $(2,523,556) | $(1,931,787) |
Debt & Liquidity: The Company holds approximately $10,000 in cash. Significant liabilities include $516,643 in accrued preferred stock dividends and multiple notes payable in default. The filing explicitly states that the Company has limited financial resources to pay current expenses, raising substantial doubt about its ability to continue as a going concern.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 25% year-over-year ($28,201 vs. $37,383) as the legacy warranty business continues to run off with no new revenue from royalty interests.
- Expense Increase: Selling, general, and administrative (SG&A) expenses increased by approximately $603,000 (118% increase) to $1.11 million, driven by higher payroll, professional fees, and investment banking costs.
- Net Loss Improvement: Despite higher operating expenses, the net loss decreased by $230,794 (16%) primarily due to a $130,000 reduction in interest expense resulting from lower rates and debt repayments.
- Liquidity Deterioration: Cash and equivalents dropped from $27,868 at year-end 2004 to $10,377 at September 30, 2005.
Outlook, Risks, and Contingencies
- Going Concern: Management states there is substantial doubt about the Company's ability to continue as a going concern due to limited resources and lack of operations.
- Debt Defaults: Multiple notes totaling over $500,000 are in default. These include notes from 2003, 2004, and 2005 bearing interest rates between 8% and 20%.
- Failed Royalty Venture: A proof-of-concept study with Parallel Solutions, Inc. (PSI) failed to meet success standards. PSI has no definitive plans to move forward, substantially reducing the likelihood of future royalty revenue from this $720,000 investment.
- Financing Needs: The Company is attempting to raise $1.5 million in equity to fund obligations to partners (Healthwave, NeoStem) and pay debts. A private placement of convertible notes expired in August 2005 without closing.
- Acquisition Intent: The Company signed a non-binding letter of intent to acquire NeoStem's adult stem cell assets in exchange for common stock, contingent on financing.
Investor Verification Checklist
- Cash Runway: Verify if the $10,377 cash balance is sufficient to meet immediate payroll and debt obligations given the "substantial doubt" disclosure.
- Debt Default Status: Confirm the status of the $500,000+ in defaulted notes and whether creditors are pursuing legal action or demanding immediate repayment.
- Financing Progress: Determine if the Company has successfully raised the required $1.5 million equity financing to fund its revenue-sharing agreements with Healthwave and NeoStem.
- NeoStem Acquisition: Verify if the non-binding letter of intent to acquire NeoStem has been converted into a binding agreement and if the stock issuance for the purchase price has been approved.
- Preferred Stock Dividends: Assess the impact of the $516,643 in accrued dividends on Series A Preferred Stock and the potential for forced redemption or conversion.